Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD.

Lancet Oncol. 2018 Nov 12. pii: S1470-2045(18)30576-X. doi: 10.1016/S1470-2045(18)30576-X. [Epub ahead of print]

PMID:
30442502
2.

The power of proteasome inhibition in multiple myeloma.

Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG.

Expert Rev Proteomics. 2018 Nov 14:1-20. doi: 10.1080/14789450.2018.1543595. [Epub ahead of print]

PMID:
30427223
3.

Ixazomib for the treatment of multiple myeloma.

Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S.

Expert Opin Pharmacother. 2018 Nov 13:1-20. doi: 10.1080/14656566.2018.1528229. [Epub ahead of print]

PMID:
30422008
4.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

5.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.

N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

PMID:
30403938
6.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Richardson PG, Grupp SA, Pagliuca A, Krishnan A, Ho VT, Corbacioglu S.

Int J Hematol Oncol. 2017 Nov;6(3):75-93. doi: 10.2217/ijh-2017-0015. Epub 2017 Aug 11. Review.

7.

A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin MG, Reynolds CH, Shain K, Zackon I, Stampleman L, Henrick P, Rivotto BJ, Hornburg K, Dumke H, Chuma S, Savell A, Handisides D, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.

Clin Cancer Res. 2018 Oct 2. pii: clincanres.1325.2018. doi: 10.1158/1078-0432.CCR-18-1325. [Epub ahead of print]

PMID:
30279233
8.

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Downey-Kopyscinski S, Daily EW, Gautier M, Bhatt A, Florea BI, Mitsiades CS, Richardson PG, Driessen C, Overkleeft HS, Kisselev AF.

Blood Adv. 2018 Oct 9;2(19):2443-2451. doi: 10.1182/bloodadvances.2018016360.

9.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Sep 24. pii: blood-2018-06-858613. doi: 10.1182/blood-2018-06-858613. [Epub ahead of print]

PMID:
30249784
10.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5.

PMID:
30218008
11.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.

Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.

PMID:
30204239
12.

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG.

Clin Adv Hematol Oncol. 2018 Aug;16(8):564-574. Review.

PMID:
30148829
13.

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS.

JAMA Oncol. 2018 Aug 16:e183267. doi: 10.1001/jamaoncol.2018.3267. [Epub ahead of print]

PMID:
30128502
14.

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2018 Aug 3. pii: S1083-8791(18)30428-2. doi: 10.1016/j.bbmt.2018.07.039. [Epub ahead of print]

PMID:
30081073
15.

How I treat the young patient with multiple myeloma.

Gandolfi S, Prada CP, Richardson PG.

Blood. 2018 Sep 13;132(11):1114-1124. doi: 10.1182/blood-2017-05-693606. Epub 2018 Jul 2. Review.

PMID:
29967130
16.

The use of defibrotide in blood and marrow transplantation.

Richardson PG, Carreras E, Iacobelli M, Nejadnik B.

Blood Adv. 2018 Jun 26;2(12):1495-1509. doi: 10.1182/bloodadvances.2017008375. Review. Erratum in: Blood Adv. 2018 Aug 14;2(15):1853.

17.

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R.

Br J Haematol. 2018 Jul;182(2):231-244. doi: 10.1111/bjh.15394. Epub 2018 Jun 25.

18.

Maintenance and continuous therapy for multiple myeloma.

Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P.

Expert Rev Anticancer Ther. 2018 Aug;18(8):751-764. doi: 10.1080/14737140.2018.1490181. Epub 2018 Jul 3.

PMID:
29932776
19.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R, Tappe W, Soiffer RJ, Grupp SA.

Pediatr Blood Cancer. 2018 Oct;65(10):e27269. doi: 10.1002/pbc.27269. Epub 2018 Jun 6.

PMID:
29873895
20.

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG.

Br J Haematol. 2018 Aug;182(4):495-503. doi: 10.1111/bjh.15384. Epub 2018 May 29.

21.

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.

Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, Lonial S.

Br J Haematol. 2018 Jun;181(5):628-636. doi: 10.1111/bjh.15248. Epub 2018 May 17.

PMID:
29774521
22.

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.

Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG.

Leukemia. 2018 Aug;32(8):1838-1841. doi: 10.1038/s41375-018-0115-z. Epub 2018 Mar 27. No abstract available.

PMID:
29749395
23.

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Varga C, Laubach JP, Anderson KC, Richardson PG.

Br J Haematol. 2018 May;181(4):433-446. doi: 10.1111/bjh.15116. Epub 2018 May 10. Review.

PMID:
29748955
24.

Meaningful changes in end-of-life care among patients with myeloma.

Odejide OO, Li L, Cronin AM, Murillo A, Richardson PG, Anderson KC, Abel GA.

Haematologica. 2018 Aug;103(8):1380-1389. doi: 10.3324/haematol.2018.187609. Epub 2018 May 10.

25.

Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.

Hari P, Lin HM, Zhu Y, Berg D, Richardson PG, Moreau P.

J Med Econ. 2018 Aug;21(8):793-798. doi: 10.1080/13696998.2018.1474745. Epub 2018 May 29.

PMID:
29741409
26.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.

Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8.

27.

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosiñol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, Zhu Y, Skacel T, Moreau P, Richardson PG.

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25134. [Epub ahead of print]

PMID:
29726031
28.

Current use of monoclonal antibodies in the treatment of multiple myeloma.

Varga C, Maglio M, Ghobrial IM, Richardson PG.

Br J Haematol. 2018 May;181(4):447-459. doi: 10.1111/bjh.15121. Epub 2018 Apr 25. Review.

PMID:
29696629
29.

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1.

Garderet L, Laubach JP, Stoppa AM, Hari P, Cavo M, Ludwig H, Mateos MV, Luptakova K, Lin J, Yung G, van de Velde H, Berg D, Moreau P, Richardson PG.

Leukemia. 2018 Sep;32(9):2032-2036. doi: 10.1038/s41375-018-0091-3. Epub 2018 Mar 12. No abstract available.

30.

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R.

Br J Haematol. 2018 Mar;180(6):821-830. doi: 10.1111/bjh.15058. Epub 2018 Feb 13.

31.

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.

Pandit A, Leblebjian H, Hammond SP, Laubach JP, Richardson PG, Baden LR, Marty FM, Issa NC.

Bone Marrow Transplant. 2018 Jul;53(7):942-945. doi: 10.1038/s41409-018-0112-x. Epub 2018 Feb 9.

PMID:
29426830
32.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15122. [Epub ahead of print] No abstract available.

PMID:
29411874
33.

Ixazomib-induced cutaneous necrotizing vasculitis.

Alloo A, Khosravi H, Granter SR, Jadeja SM, Richardson PG, Castillo JJ, LeBoeuf NR.

Support Care Cancer. 2018 Jul;26(7):2247-2250. doi: 10.1007/s00520-018-4052-1. Epub 2018 Feb 1.

PMID:
29392482
34.

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Richardson PG, Triplett BM, Ho VT, Chao N, Dignan FL, Maglio M, Mohty M.

Expert Rev Clin Pharmacol. 2018 Feb;11(2):113-124. doi: 10.1080/17512433.2018.1421943. Epub 2018 Jan 5. Review.

PMID:
29301447
35.

Optimizing therapy for del(17p) multiple myeloma.

Avet-Loiseau H, Richardson PG, di Bacco A.

Oncotarget. 2017 Dec 6;8(66):109859-109860. doi: 10.18632/oncotarget.22987. eCollection 2017 Dec 15. No abstract available.

36.

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Richardson PG, Attal M, Campana F, Le-Guennec S, Hui AM, Risse ML, Corzo K, Anderson KC.

Future Oncol. 2018 May;14(11):1035-1047. doi: 10.2217/fon-2017-0616. Epub 2017 Dec 22.

37.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16. Review.

38.

The proteasome and proteasome inhibitors in multiple myeloma.

Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG.

Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8. Review.

PMID:
29196868
39.

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Richardson PG, Holstein SA, Schlossman RL, Anderson KC, Attal M, McCarthy PL.

Expert Opin Pharmacother. 2017 Dec;18(18):1975-1985. doi: 10.1080/14656566.2017.1409207. Epub 2017 Dec 1. Review.

PMID:
29172855
40.

CD38 antibodies in multiple myeloma: back to the future.

van de Donk NWCJ, Richardson PG, Malavasi F.

Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8. Review.

PMID:
29118010
41.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

PMID:
29054911
42.

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J.

Br J Haematol. 2017 Dec;179(5):756-771. doi: 10.1111/bjh.14974. Epub 2017 Oct 19.

PMID:
29048129
43.

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J.

Br J Haematol. 2018 Jan;180(2):271-275. doi: 10.1111/bjh.14970. Epub 2017 Oct 19.

PMID:
29048105
44.

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.

Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XS.

Clin Pharmacokinet. 2018 Apr;57(4):529-538. doi: 10.1007/s40262-017-0598-1.

45.

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D, van de Velde H, Moreau P.

J Blood Med. 2017 Aug 22;8:107-121. doi: 10.2147/JBM.S102328. eCollection 2017. Review.

46.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332.

47.

Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.

Corbacioglu S, Richardson PG.

Expert Rev Gastroenterol Hepatol. 2017 Oct;11(10):885-898. doi: 10.1080/17474124.2017.1370372. Epub 2017 Sep 4.

PMID:
28825848
48.

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.

Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K.

Target Oncol. 2017 Oct;12(5):643-654. doi: 10.1007/s11523-017-0524-3.

49.

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, Lankester A, Locatelli F, Pagliuca A, Peters C, Richardson PG, Schulz AS, Sedlacek P, Stein J, Sykora KW, Toporski J, Trigoso E, Vetteranta K, Wachowiak J, Wallhult E, Wynn R, Yaniv I, Yesilipek A, Mohty M, Bader P.

Bone Marrow Transplant. 2018 Feb;53(2):138-145. doi: 10.1038/bmt.2017.161. Epub 2017 Jul 31.

50.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P.

Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27.

Supplemental Content

Loading ...
Support Center